Prosecution Insights
Last updated: October 02, 2026

Examiner: MOSS, NATALIE M

Tech Center 1600 • Art Units: 1651 1653

This examiner grants 31% of resolved cases

Analysis

Natalie M Moss is an examiner in Tech Center 1600 and Art Unit 1651. She has 523 resolved cases, with an allowance rate of 30.8 percent. The median days to allowance is 1414. These figures indicate a challenging environment for applicants and a long timeframe for prosecution in this unit.

The interview lift is 17.1 percent, showing that interviews can help improve the odds of success. Even with a 30.8 percent allowance rate, an interview provides a 17.1 percent increase in the likelihood of allowance. Practitioners should consider this lift as a way to overcome the difficulties indicated by the baseline metrics.

The 523 resolved cases provide a solid statistical foundation for Art Unit 1651. The 1414 day median and allowance rate are critical for planning. The interview lift is a valuable data point for those seeking to optimize their prosecution strategy and manage client expectations regarding the likely outcome.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

30.8%
Allow Rate
-29.2% vs TC avg
599
Total Applications
+17.1%
Interview Lift
1414
Avg Prosecution Days
Based on 523 resolved cases, 2023–2026

Rejection Statute Breakdown

7.9%
§101 Eligibility
13.3%
§102 Novelty
45.6%
§103 Obviousness
28.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
14239690 PROCESS FOR PRODUCING CELLULASES USING A FILAMENTOUS FUNGUS SUITABLE FOR A FERMENTER, HAVING A LOW VOLUMETRIC OXYGEN TRANSFER COEFFICIENT KLA Non-Final OA IFP ENERGIES NOUVELLES
17602458 CELL CULTURE MEDIA COMPRISING KETO ACIDS Non-Final OA MERCK PATENT GMBH
17964325 METHOD FOR MEDIUM TREATMENT BEFORE INOCULATION Non-Final OA Genentech, Inc.
18227801 Methods for Antimicrobial Susceptibility Testing Final Rejection The Regents of the University of California
18237744 NANOFIBER-HYDROGEL COMPOSITES FOR CELL AND TISSUE DELIVERY Non-Final OA The Johns Hopkins University
17439251 ISOLATION, ENRICHMENT AND EXPANSION OF CONE PROGENITOR CELLS AND USES THEREOF Non-Final OA Massachusetts Institute of Technology
17914691 METHODS OF USING UMBILICAL CORD PRODUCTS FOR TREATMENT OF OCULAR SURFACE DISORDERS Non-Final OA BIOTISSUE HOLDINGS INC.
17879015 Method of Recovering Nitrogen and Sulfur Resources Through Anaerobic Fermentation Final Rejection SK Innovation Co., Ltd.
17541558 FASTING MIMICKING KETOGENIC DIET (FMD) TO PROMOTE SKELETAL MUSCLE REGENERATION AND STRENGTH Final Rejection UNIVERSITY OF SOUTHERN CALIFORNIA
18359053 METHOD FOR PROMOTING PROLIFERATION AND PLURIPOTENCY FACTOR EXPRESSION OF STEM CELLS AND COMPOSITION PRODUCED USING THE SAME Final Rejection BUDDHIST TZU CHI MEDICAL FOUNDATION
18648537 COMPOSITION FOR CELL ADDITION Non-Final OA AGC INC.
17180189 METHOD FOR DETECTION AND ANALYSIS OF CEREBROSPINAL FLUID ASSOCIATED UBE3A Non-Final OA University of South Florida
18258403 BLOOD SAMPLER CONTAINING ANTI-PLATELET AGENT AND WATER-SOLUBLE MATRIX MATERIAL Non-Final OA Radiometer Medical ApS
18605672 SYSTEMS AND METHODS FOR EX VIVO ORGAN CARE Non-Final OA TransMedics, Inc.
17995138 STABILIZING COMPOSITION AND METHOD FOR PRESERVING A BODILY FLUID Final Rejection DNA Genotek Inc.
14398210 DOSING REGIMENS FOR THE TREATMENT OF POMPE DISEASE Non-Final OA Amicus Therapeutics, Inc.
16467358 DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY Non-Final OA St. Jude Children's Research Hospital
17755834 FIBROBLAST THERAPY FOR INFLAMMATORY BOWEL DISEASE Final Rejection FIGENE, LLC
16519384 Method of Producing a Mycological Product and Product Made Thereby Final Rejection Ecovative LLC
17610894 METHOD FOR REDUCING METHIONINE OXIDATION IN RECOMBINANT PROTEINS Non-Final OA FORMYCON AG
17435911 METHOD FOR DETERMINING EFFICACY Non-Final OA LDN Pharma Limited
17259784 INJECTION TECHNIQUES FOR THE TREATMENT OF CELLULITE Non-Final OA ENDO OPERATIONS LIMITED
16690197 Novel methods for delivering therapeutics agents to the eye via the nasal passages Non-Final OA Noveome Biotherapeutics, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month